Table III. Airway mucosal eosinophils % change from baseline (ATP population).
| Cohort | Group, Endpoint | N | Median % Change from baseline | P Value Benralizumab vs. placebo | P Value Baseline vs. endpoint | |
|---|---|---|---|---|---|---|
| 1 (IV) | Placebo, Day 28 | 5 | 19.6 | 1 | ||
| Benralizumab 1 mg/kg, Day 28 | 8 | −61.9 | .28a | .29b | ||
|
| ||||||
| 2 (SC) | Placebo, Day 84 | 5 | −46.7 | 1 | ||
| Benralizumab 100+200 mg, Day 84 | 9 | −95.8 | .06a | .01b | ||
|
| ||||||
| 1+2 | Placebo, 28 days after last dose | 10 | 4.7 | 1 | ||
| Benralizumab, 28 days after last dose | 17 | −83.1 | .02c | 0.0023b | ||
ATP = according to protocol; IV = intravenous; SC = subcutaneous.
a
Prespecified Wilcoxon rank-sum test of % change from baseline.
b
Post-hoc Sign test of absolute eosinophil counts.
c
Post-hoc Wilcoxon rank-sum test of % change from baseline.